The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 2 November 2004, www.theannals.com, DOI 10.1345/aph.1E085.
 The Annals of Pharmacotherapy: Vol. 38, No. 12, pp. 2122-2127. DOI 10.1345/aph.1E085
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow A correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ehret, M. J
Right arrow Articles by Fuller, M. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ehret, M. J
Right arrow Articles by Fuller, M. A

NEW DRUG APPROVALS

Long-Acting Injectable Risperidone

Megan J Ehret, PharmD

Psychiatry Pharmacy Resident, Cleveland Department of Veterans Affairs Medical Center, Brecksville, OH

Matthew A Fuller, PharmD BCPS BCPP FASHP

Clinical Pharmacy Specialist, Psychiatry, Cleveland Department of Veterans Affairs Medical Center; Associate Clinical Professor of Psychiatry, Clinical Instructor of Psychology, Case Western Reserve University, Cleveland, OH; Adjunct Associate Professor of Clinical Pharmacy, University of Toledo, Toledo, OH

Reprints: Matthew A Fuller PharmD BCPS BCPP FASHP, Louis Stokes Cleveland Veterans Affairs Medical Center, 10000 Brecksville Rd., Pharmacy Service 119(B), Brecksville, OH 44141-3204, fax 440/546-2706, Matthew.Fuller{at}med.va.gov

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of long-acting (LA) risperidone for the treatment of schizophrenia.

DATA SOURCES: Information was selected from PubMed (1965–July 2004). Applicable scientific posters were also used.

STUDY SELECTION AND DATA EXTRACTION: All published information on risperidone LA was considered. Material providing a comprehensive description was considered.

DATA SYNTHESIS: Risperidone LA is the first long-acting, injectable atypical antipsychotic. It is dosed at 25–50 mg every 2 weeks. Adverse effects are similar to those seen with oral risperidone. A short-term study showed that risperidone LA is better than placebo in reducing the signs and symptoms of schizophrenia, and a long-term trial showed that stable schizophrenic patients can be switched from either oral or other injectable antipsychotic medications to risperidone LA.

CONCLUSIONS: Risperidone LA is efficacious and safe in the treatment of schizophrenia.

Key Words: long-acting risperidone, schizophrenia

Published Online, November 2, 2004. www.theannals.com, DOI 10.1345/aph.1E085




homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.